Provider review
ShedRx (Shed) review
Drops and lozenges beside the injection — the formats that make taking less practical.
A drop or a lozenge is a far more forgiving vehicle for a fraction of a dose than a part-filled syringe.
Price as published
GLP-1 liquid drops from $229/mo · lozenges from $199/mo · compounded semaglutide injection $199/mo · tirzepatide injection $299/mo (both fall on 6- and 12-month plans)
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
ShedRx is a platform rather than a single-format prescriber, and the format range is the whole argument for a low-dose reader: liquid drops and lozenges sit beside the standard weekly injection, and both are a far more forgiving way to take less than trying to draw a partial unit from a vial. Brand Zepbound and Wegovy are available if you move to a standard dose, coaching is included, and it prescribes in all 50 states. The catch is that the most dose-flexible format is also the priciest, the lowest advertised rate is a twelve-month commitment, and the dispensing pharmacy is not publicly named.
The trade-off we would want you to read first
The advertised "as low as $239" tirzepatide rate is a TWELVE-MONTH commitment — month-to-month is $299
Who it suits, and who it does not
A good fit if
- You want a format you can meaningfully take a fraction of, not a syringe you part-fill
- You may want to move to a brand-name product at a standard dose later
- You want coaching included rather than sold separately
Look elsewhere if
- You will not sign a twelve-month commitment to reach the advertised rate
- You want the dose-flexible format to be the cheapest one — here it is the most expensive
- You want the compounding pharmacy named
How the programme works
A weight-loss platform rather than a single-format prescriber, and the format range is the point for a low-dose reader: GLP-1 liquid drops and lozenges sit alongside the standard weekly injection, and a drop or lozenge is a far more forgiving vehicle for taking less than a full dose than trying to draw a partial unit from a vial. Brand Zepbound and Wegovy are available for anyone who wants to switch tracks, health coaching is included with membership, and GLP-1s are prescribed in all 50 states.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Not publicly identified
- Labs
- Not required
- Dietitian support
- Included
Strengths
- Liquid drops and lozenges — the two formats that make a genuinely small dose practical, rather than asking you to part-fill a syringe
- Both molecules injectable too, plus brand Zepbound and Wegovy if you move to a standard dose
- Health coaching included with membership, and a published 120-day weight-loss guarantee
- Available in all 50 states
The other trade-offs
- Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
- Drops at $229/mo cost more than the $199 lozenge or injection, so the most dose-flexible format is also the priciest
- The dispensing compounding pharmacy is not publicly named
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
ShedRx (Shed) is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.